Enfortumab-vedotin plus pembrolizumab offers survival benefits but is less cost-effective than gemcitabine and cisplatin plus nivolumab, especially in Europe. Healthcare providers face challenges ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results